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Abstract
Background: Expression of the Sp1 transcription factor is induced by hypoxia, and the ADAM17
promoter contains predicted Sp1 binding sites. ADAM17 contributes to hypoxic-induce
invasiveness of glioma. In this study, we investigated whether Sp1 transcription factor induces
ADAM17 and/or contributes to tumor cell invasiveness in hypoxia.
Methods: Employing RT-PCR and Western blot, we examined the role of Sp1 in ADAM17
transcription/expression under normoxic and hypoxic conditions, and whether it binds to the
ADAM17 GC-rich promoter region using a chromatin immunoprecipitation assay. Additionally, we
tested the effect of Sp1 suppression in tumor cell invasion and migration, using Matrigel basement
membrane invasion chambers, a scratch wound-healing assay, and small interfering RNA.
Results: Here, we found that Sp1 binds to the ADAM17 promoter, and that Sp1 regulates
ADAM17 expression under hypoxia. Furthermore, suppression of Sp1 decreases invasiveness and
migration in U87 tumor cells.
Conclusion: Our findings suggest the Sp1 transcription factor mediates ADAM17 expression
under hypoxia, regulates glioma invasiveness, and thus, may be a target for anti-invasion therapies.
Background
Brain tumors result from abnormal or uncontrolled cell
division. Glioma is a highly vascular, very aggressive and
extremely invasive primary brain tumor. Hypoxia induces
changes in glioma and its microenvironment, which leads
to increased aggressiveness and resistance to chemother-
apy and radiation [1]. Studies have shown that large areas
of hypoxia within glioma correlates inversely with the
patient's outcome and survival [1-4].
ADAM17 (A Disintegrin and Metalloproteinase-17) also
called TACE (TNF-alpha converting enzyme) plays a piv-
otal role in the processing of numerous growth factor pro-
teins, and has emerged as a new therapeutic target in
several tumor types [5-8]. Recent studies showed that
when ADAM17 is either inhibited or suppressed there is
attenuation in tumor invasiveness and malignancy, result-
ing in a better outcome for breast cancer patients [9,10].
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Low levels of oxygen (hypoxia) initiates cellular invasive
processes that occur under physiological and pathological
conditions such as tumor invasiveness and metastasis
[11].
Specificity transcription protein-1 (Sp1) is believed to
play an important role in the transcription of many genes
involved in cancer that have an abundance of GC boxes in
their promoter region [12-15]. Currently, the role of Sp1
in ADAM17 expression and activity is unknown, but it is
known the ADAM17 promoter region contains GC-rich
sequences highly complementary to the Sp1 DNA-bind-
ing site [16]. Hypoxia induces expression of ADAM17 and
increases invasiveness of glioma in vitro [6].
In this study, we investigated if Sp1 protein plays a role in
ADAM17 transcription, and if Sp1 regulates hypoxic-
induced ADAM17 expression in U87 human glioma cells.
In addition, we examined the function of Sp1 in tumor
invasiveness under normoxic and hypoxic conditions.
Methods
Cell culture
The U87 tumor cell line was obtain from American Type
Culture Collection (ATCC) The cells were grown in
DMEM (Dulbeco Modified Essential Medium) which
contained 10% FBS (Fetal Bovine Serum),100 IU/mL pen-
icillin, 100 μg/mL streptomycin (Life Technologies). The
cells were passed once a week after trypsinization (0.05%
trypsin-ethylenediaminetetraacetic acid; Life Technol-
ogy).
Hypoxic culture conditions
The hypoxia experiments were performed in an anaerobic
chamber (model 1025; Forma Scientific) which was satu-
rated with 85%N2/10%H2/5%CO2. The temperature in
the anaerobic chamber was set at 37°C and the oxygen
level was below 1%. The media was changed before the
experiment with DMEM low glucose and 10% FBS. The
cells were harvested at 8, 12, 16 and 20 hours. In parallel
with the hypoxic culture, normoxic culture was harvested
as well to serve as a control for all assays.
Chromatin immunoprecipitation assay (ChIP)
ChIP assay was performed as follows: U87 (1 × 106) cells
on a 10 cm dish were treated with 1% formaldehyde and
incubated for 10 min at 37°C, then washed with cold PBS
containing protease inhibitors (1 mM phenylmethylsulfo-
nyl fluoride-PMSF, 1 μg/mL aprotinin and 1 μg/mL pep-
statin A). The cells were collected, spun down and added
SDS lysis buffer, and then incubated on ice. The DNA was
sonicated (5 pulses for 10 s, chilled on ice for 50 s) to
shear it into 200-1000 base pairs. Once the sheared DNA
was diluted into ChIP buffer a pellet was obtain by centrif-
ugation. The assay requires two negative controls. The first
control was transcriptionally inactivated DNA that was
used for the PCR reaction, and the second control was
transcriptionally active DNA without antibody for
immuno-precipitation. The immuno-precipitating Sp1
antibody was added to the DNA and incubated overnight.
PCR (Polymerase Chain Reaction) was done in order to
amplify the DNA that was bound to the immunoprecipi-
tated histones. The primers used for amplification were
design using OligoPerfect Primer Design Program (Invit-
rogen) and are as follows: A17 1F 5'-TGGAGCAAATGT-
GCATTCAG-3', A17 1R 5'-GCATTTGGTTCAGGGTCCTA-
3', A17 2F 5'- GTGGGCATCAAGACAAAGGA-3', A17 2R
5'-CTTCCTGGACGCAGACGTA-3', A17 3F 5'-GAGCCT-
GGCGGTAGAATCTT-3', A17 3R 5'-TACCGACTCCAC-
CTCTCTGG-3'. Once amplified, the PCR product was
tested by electrophoresis on a 2% agarose gel containing
0.01% ethidium bromide. The results were visualized
using DualLite Trans-illuminator machine (Fisher). The
ChIP assay was performed under normoxic conditions.
Real-time PCR
Quantitative RT-PCR was performed using real-time PCR
with the SYBR Green reporter. The RNA was isolated from
the cell cultures by using the Absolutely RNA Miniprep Kit
(Stratagene). RNA yield was determined with OD260 nm.
RNA was reverse transcribed to complementary DNA
using the M-MLV RT protocol (Invitrogen). Quantitative
RT-PCR was performed after stabilizing the RNA. The kit
used for RT-PCR was a SYBR Green PCR master kit with
the appropriate forward and reverse primers (Invitrogen),
which were optimized to the desired concentration (10
nM). The instrument used for this experiment was ABI
7000 PCR machine (Applied Biosystems). Each sample
was tested three times. The primers used for this experi-
ment are in Table 1. Human TATA-box binding protein
was used as an internal control.
Western blot
Proteins were extracted from the cell culture and the
added in 500 μL lysis buffer with 1% protease inhibitor
cocktail (1 mM phenylmethylsulfonyl fluoride-PMSF, 1
μg/mL aprotinin and 1 μg/mL pepstatin A). The concen-
tration of the proteins was determined by Bicinchoninic
acid assay (BCA) following the protocol provided by the
manufacturer (Pierce). Equal amounts of proteins mixed
with NuPage loading buffer were loaded on a 12% Bris-
Tris Gels (Invitrogen) after being denatured. After block-
age the membrane was incubated using primary antibod-
ies, which were added against ADAM17 (Abcam), HIF-1α
(Cell Signaling), Sp1 (Santa Cruz) or β-Actin (Abcam) in
PBS-T containing 5% milk overnight at 4°C. Subse-
quently, the membrane was washed with PBS-T for 45
minutes at room temperature, followed by incubation
with the secondary antibodies for 1 hr and 30 min, still at
room temperature. The immunoblots were detected, fol-Journal of Experimental & Clinical Cancer Research 2009, 28:129 http://www.jeccr.com/content/28/1/129
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lowing a second washing, using the SuperSignal West Pico
Chemiluminescent Substrate kit (Pierce). The internal
control for Western blots was β-Actin.
Alpha-secretase assay
After U87 tumor cells were harvested, lysis buffer was
added to the tubes. Proteins were sonicated five times for
10 sec each time. A BCA protein assay (Thermo Scientific)
was done in order to find the protein concentration of
each sample. A total volume of 200 μl proteins with buff-
ers were added to the alpha-secretase specific APP (amy-
loid precursor protein) peptide. Two wells were used as
control, where only buffer was added to them. Fluores-
cence was read using a Fusion multiplate reader (Packard
Bioscience).
In vitro invasion assay
Matrigel invasion assay (BD Biosciences) was employed
to test cell invasion. The membrane was soaked in DMEM
low glucose and incubated for one hour at 37°C. The bot-
tom well contained high glucose DMEM containing
serum. Cells were added to the upper well and incubated
for 24 hours at 37°C with 5% CO2. After incubation, Cell
Tracker (Invitrogen) dye was added to the wells for 20
minutes. Cells were fixed with 4% paraformaldehyde; the
membrane was removed, and then transferred to slides for
analysis.
In vitro wound-repair assay
This assay was used to assess cell migration. In a 24-well
plate, U87 tumor cells were added to high glucose DMEM
media, and incubated for two hours in order to create a
monolayer of cells. A scratch was made in the middle of
the well with a p200 pipette tip. The debris was washed
away and new media added to the wells. Under the micro-
scope, the cells were imaged and the initial area of the
scratch for the field of view was determined by multiply-
ing the length by the average width of the area devoid of
cells. The plate was incubated at 37°C for 12 hours, after
which the same field of view was imaged and the area
devoid of cells was recalculated by the same method. The
final area of the scratch wound was divided by the initial
area, giving us the % of the initial area covered by migrat-
ing cells over the 12 hours culture period.
siRNA transfection
A stable transfection of Sp1 siRNA was carried out using
Lipofectamine 2000 transfection reagent (Invitrogen).
The transfection reagent and the siRNA were diluted in
100 μL DMEM without serum or antibiotic. Once they
were mixed together, they were incubated for 20 minutes
at room temperature. For each transfection 6 mL DMEM
was added to each tube containing the siRNA-transfection
mixture. Clonal selection of neomycin-resistant U87 cells
was conducted after transfection. Sp1 down-regulation
was verified in transfected U87 clones using Western blot.
The cells were maintained in neomycin-containing
media, and employed less than 10 passages after confir-
mation of reduced Sp1 protein expression. Of note, Sp1
down-regulation in U87 cells caused cells to acquire a flat,
less bipolar morphology compared to control transfected
cells. All Sp1 shRNA-expressing clones shared this mor-
phology whereas control plasmid transfected clones did
not, suggesting the effect was due to Sp1 down-regulation.
Results and discussion
Sp1 binds to the ADAM17 promoter
Sp1 binds to GC boxes in the promoter region of genes to
regulate their expression. It has been suggested that
ADAM17 is one of these genes [16]. Using the ChIP assay,
we tested whether the Sp1 transcription factor binds to the
ADAM17 promoter region. Employing three fragments of
the ADAM17 promoter (GenBank: AB034151.1), results
of PCR amplification indicated Sp1 bound to the frag-
ment corresponding to the first 97 bp of the ADAM17 pro-
moter region (Figure 1A), corresponding to (1-97 of
Table 1: The primers used for real time polymerase chain reaction
Gene GenBank accession number Sequence








ADAM17, a disintegrin and a metalloproteinase-17; HIF-1α, hypoxia inducible factor-1 alpha; Sp1, specificity transcription protein -1; TBP, TATA-
binding protein.Journal of Experimental & Clinical Cancer Research 2009, 28:129 http://www.jeccr.com/content/28/1/129
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AB034151.1, -901 to -804 of the ADAM17 initiation
codon). The human Sp1 consensus sequence starts at base
pair 3 and the length is 6 base pairs long, indicating a
probable binding site (Figure 1B).
Hypoxia up-regulates ADAM17 and Sp1 in U87 tumor cells
Real-time RT-PCR was performed to determine whether
Sp1 transcription factor mediates ADAM17 expression
under normoxic and hypoxic conditions. Real-time RT-
PCR analysis of ADAM17, Sp1 and HIF-1α mRNA was
performed on U87 tumor cells. Human TATA-Box protein
was used as a normalizing control, and HIF-1α was used
as a positive marker for hypoxia. The mRNA samples used
for PCR were normoxic control, 8 hours, 12 hours, 16
hours and 20 hours of hypoxia. Sp1 mRNA expression
peaked after 12 hours of hypoxic incubation. Significant
increases (*P < 0.05) were observed in the mRNA levels of
ADAM17, Sp1 and Hif-1α genes under hypoxic compared
to normoxic conditions (Figure 2A). To test the contribu-
tion of Sp1 to ADAM17 expression, we established a Sp1-
deficient cell-line by transfecting U87 cells with a plasmid
encoding for Sp1-targeting siRNA. U87 cells transfected
with empty pcDNA3.1+ vector were used as control.
Employing these cells in our hypoxic incubation assay, we
found that the mRNA expression levels of ADAM17 and
Sp1 were significantly (*P < 0.05) lower compared to the
results obtained from respective control (Figure 2C). Of
note, HIF-1α mRNA levels were also affected by inhibi-
tion of Sp1, and were significantly decreased compared to
control HIF-1α mRNA expression under hypoxic condi-
tions (Figure 2C). This is likely due to the fact that Sp1 is
a known transcription factor for HIF-1α [17]. These results
suggest that ADAM17 mRNA expression is altered by the
Sp1 transcription factor, particularly ADAM17 transcrip-
tion induced by hypoxia.
Western blot was employed to determine the protein
expression of Sp1, ADAM17 and HIF-1α. In addition, we
tested whether Sp1 down-regulation affects ADAM17
expression levels under normoxic and hypoxic condi-
tions. β-Actin protein was used as a loading control and
HIF-1α protein was used as a positive marker for hypoxia.
Western blotting revealed an increase ADAM17, Sp1 and
HIF-1α protein expression under hypoxic conditions
compared to normoxic control. The blots of all three pro-
teins increased under hypoxia, and peaked at 12 hours of
hypoxic incubation within the time points where expres-
sion was measured (Fig 2B). When Sp1-deficient cells
were used for the experiment, a significant decrease in
ADAM17 protein expression levels was observed after 12
hours of culture, both under normoxic and hypoxic con-
ditions (Figure 2D). These data indicate that under
hypoxic conditions ADAM17 and Sp1 protein levels
increased significantly but decreased when Sp1 is down-
regulated. In addition, ADAM17 protein is decreased in
Sp1 deficient cells under normoxic conditions as well.
Based on these results, we concluded that the Sp1 tran-
scription factor plays a significant role in controlling
ADAM17 protein expression, particularly under hypoxic
conditions. As Sp1 and ADAM17 protein expression
peaked at 12 hours hypoxia, we employed this time point
for our further hypoxic assays.
Hypoxic-induced alpha-secretase assay in U87 is Sp1 
dependent
Previously, we reported that ADAM17 contributes to
hypoxic-induced tumor invasion [6]. Having established
that Sp1 mediates hypoxic-induced ADAM17 expression,
we tested whether Sp1 down-regulation would elicit an
anti-invasion effect, similar to inhibition of ADAM17.
ADAM17 is an alpha-secretase, capable of proteolytic
cleavage of APP into its soluble APP-alpha peptide [18].
Therefore we tested if the Sp1 transcription factor alters
ADAM17 alpha-secretase activity in normoxic and
hypoxic conditions. Hypoxic incubation of U87 for 12
hours increased alpha-secretase activity by 43.6% com-
pared to normoxic control (Figure 3). This agreed with our
previous findings that hypoxia induced alpha-secretase
activity in U87 cells, primarily via ADAM17 [6]. In con-
trast, when Sp1 was suppressed, alpha-secretase activity
under hypoxic incubation was unchanged compared to
A. Chromatin Immuno-Precipitation analysis of Sp1 binding  to the ADAM17 promoter Figure 1
A. Chromatin Immuno-Precipitation analysis of Sp1 
binding to the ADAM17 promoter. Lanes 1-3 are nega-
tive controls for immuno-precipitation. Lanes 4-6 are the 
negative controls for the DNA optimization. The band in 
lane 7 indicates Sp1 binding within the ADAM17 promoter 
within 1-97 bp sequence. Lanes 8 and 9 indicate no Sp1 bind-
ing for the 356-455 and 781-879 regions of the ADAM17 
promoter, respectively. B. The promoter sequence of 
ADAM17 from base pair one up to base pair 97. The arrows 
indicate the predicted human Sp1 binding site (3-9 bp).Journal of Experimental & Clinical Cancer Research 2009, 28:129 http://www.jeccr.com/content/28/1/129
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normoxic conditions (Figure 3). Notably, Sp1 suppres-
sion under normoxic conditions did not reduce alpha-
secretase activity, suggesting Sp1 was critical for hypoxic-
induced alpha-secretase activity, but not under normoxic
conditions. These results suggest that Sp1 is a major con-
tributor in hypoxic-induced alpha-secretase activity, pos-
sibly via suppression of hypoxia-induced ADAM17.
Hypoxic-induced invasion and migration of U87 cells is 
Sp1 dependent
Recently, we reported that the increased invasion ability
of U87 cells is mediated by elevated ADAM17 expression
and protease activity, particularly under hypoxic condi-
tions [6,19]. In this assay we investigated whether Sp1
down-regulation elicits the same anti-invasion effect as
inhibition of ADAM17 on tumor cells under hypoxia. An
in vitro Matrigel invasion assay revealed that the invasive-
ness of U87 cells incubated in 1% oxygen was 52% higher
compared to invasion under normoxic control conditions
(Figure 4A). Furthermore, Sp1 suppression reduced the
invasiveness of U87 cells by 17.3% in normoxic condi-
tions and by 28.9% under hypoxic conditions compared
to U87 control cells (Figure 4B). These results indicate the
Sp1 transcription factor contributes to the invasive pheno-
type of U87 tumor cells.
Here, we established that the Sp1 transcription factor reg-
ulates ADAM17 expression under hypoxic conditions. As
ADAM17 increases glioma invasiveness, we investigated
whether Sp1 has functional consequence in glioma cell
migration. To this end, we employed the in vitro scratch
wound-repair assay to assess the migration ability of U87
and Sp1-deficient U87 cells under hypoxic conditions.
The assay revealed that U87 tumor cells migrated 67.5%
faster under hypoxic conditions than under normoxic
conditions (Figure 5A). In contrast, Sp1 suppression
Real-time RT-PCR and Western blot for Sp1, ADAM17 and HIF-1α in U87 Figure 2
Real-time RT-PCR and Western blot for Sp1, ADAM17 and HIF-1α in U87. N: normoxic incubation, H: hypoxic 
incubation, the 8 thru 20 hours indicate time points of hypoxic incubation. Sp1-DR: stable U87 cells expressing Sp1 siRNA. A. 
RT-PCR of U87 cells subjected to normoxic and hypoxic incubation for 8, 12, 16 and 20 hours. ADAM17, Sp1 and HIF-1α 
mRNA levels significantly increase under hypoxic conditions, peaking at 12 hr incubation.*P < 0.05 compared to normoxic con-
trol. B. U87 cells harvested for Western blot were incubated under normoxic and hypoxic conditions. ADAM17, Sp1 and HIF-
1α proteins increased under hypoxic conditions, peaking after 12 hr hypoxic incubation. C. RT-PCR after 12 hour hypoxic 
incubation of U87 control and Sp1-deficient U87 cells. Sp1 down-regulation significantly decreased mRNA levels of Sp1, 
ADAM17 and HIF-1 α. *P < 0.05 compared to normoxic control. #P < 0.05 compared to hypoxic control. D. Western blots 
after 12 hour hypoxic incubation of U87 control and Sp1-deficient U87 cells. Lanes 1 and 2: U87 control. Lanes 3 and 4: Sp1-
deficient U87 cells. ADAM17, Sp1 and HIF-1α decreased compared to the control under hypoxic conditions.Journal of Experimental & Clinical Cancer Research 2009, 28:129 http://www.jeccr.com/content/28/1/129
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decreased migration of U87 cells under both normoxic
and hypoxic conditions (Figure 5B), and Sp1-deficient cell
migrated 34.5% slower under hypoxic conditions com-
pared to U87 controls.
Concluding remarks
Current literature provides evidence of an association
between hypoxic conditions and the difficulties of treat-
ing brain tumors, like glioma. Hypoxia has been impli-
cated in many aspects of tumor development,
angiogenesis and growth [2]. At the cellular level, hypoxia
induces the expression and cellular concentration of HIF-
1α. High expression of this factor leads to an increase in
cell division-tumorigenesis and appears to be a prognostic
marker for malignancy [19,20].
ADAMs comprise a family of proteins that contain both a
disintegrin and a Zn-dependent metalloproteinase [21].
These molecules are involved in gene regulation, cell
adhesion and proteolysis. The most extensively studied
protein belonging to this family is ADAM17 (a.k.a.
TACE). ADAM17 sheds a variety of epidermal growth fac-
tors receptor (EGFR)-binding ligands, including trans-
forming growth factor-alpha (TGF-α), heparin-binding
epidermal growth factor (HB-EGF), and amphiregulin
[6,22]. In addition, ADAM17 facilitates the release of sev-
eral integrins from the cell surface, and influences the
invasive activity of several cells, including brain tumor
[6,21]. Sp1 is important to the transcription of many
genes that contain GC boxes in their promoters [23]. Sp1
has been widely perceived as a basal transcription factor
since its discovery; however, increasing evidence suggests
Sp1 regulates a multiple functions critical to tumorigene-
sis and progression [12,14,23]. Knowing that ADAM17
contributes to the invasiveness of tumor cells and that Sp1
binds to its promoter region, it is possible that Sp1 tran-
scription factor may be a new target for anti-invasive ther-
apies [14,23].
Previously, we have reported that the increased invasion
ability of U87 cells under hypoxic conditions is mediated
by elevated ADAM17 expression and protease activity
[6,19]. Sp1 protein expression has been reported to
increase in tumor cells under hypoxic conditions [24]. We
used the TESS promoter analysis program to determine if
the Sp1 transcription factor binds to ADAM17, as the pro-
moter region of ADAM17 contained multiple Sp1 tran-
scription factor binding sites [16]. Using a DNA-protein
binding assay under normoxic conditions we found that
Sp1 binds to ADAM17 within the ADAM17 promoter
region, -901 to -804 of TSS. As one consensus sequence for
human Sp1 is found at bp 3-9 of the ADAM17 promoter,
we surmise this is the position of Sp1-binding; however
mutational analysis is needed to confirm this is the target
site. Sp1 down-regulation reduced expression of ADAM17
under both normal and hypoxic conditions; however, we
have not confirmed the Sp1 binding site within the
ADAM17 promoter is functional. Furthermore, it has
been demonstrated that hypoxia can not only alter expres-
sion, but enhance the binding activity of Sp1 [24]. Thus,
although we demonstrate binding of Sp1 to the ADAM17
promoter, further investigation of its transcriptional effect
upon ADAM17 is warranted.
Previous studies have shown that at the transcriptional
level, Sp1 plays a critical role in gene expression especially
under hypoxic conditions [12,23,25]. Our PCR data
revealed that hypoxia induced mRNA expression of
ADAM17 as well as Sp1. In addition, we observed that our
Sp1-deficient cells decreased mRNA expression of
ADAM17 under both normoxic and hypoxic conditions.
Using Western blot, we confirmed that hypoxia induced
protein expression of ADAM17 and Sp1. However, when
Sp1 was down-regulated by an expression plasmid encod-
ing for siRNA, hypoxia failed to induce ADAM17 mRNA
and protein expression indicating that Sp1 is required for
hypoxic-induction of ADAM17.
Previously, we have reported that increased ADAM17
expression and protease activity contributes to hypoxic-
induced tumor invasion. In this study, we established that
Sp1 regulates ADAM17 gene expression. Furthermore, we
investigated whether inhibition of Sp1 would elicit an
Effect of Sp1 small interfering RNA (siRNA) on alpha-secre- tase activity in U87 tumor cells under normoxic and hypoxic  conditions Figure 3
Effect of Sp1 small interfering RNA (siRNA) on 
alpha-secretase activity in U87 tumor cells under 
normoxic and hypoxic conditions. The incubation period 
was 12 hours. Alpha-secretase activity was significantly 
increased for U87 control cells under hypoxic compared to 
normoxic conditions. Sp1 suppression reduced alpha-secre-
tase activity in hypoxic conditions. *P < 0.05 compared to 
normoxic control. #P < 0.05 compared to hypoxic control.Journal of Experimental & Clinical Cancer Research 2009, 28:129 http://www.jeccr.com/content/28/1/129
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Effect of Sp1 siRNA transfection upon invasiveness of U87 tumor cells under normoxic and hypoxic conditions Figure 4
Effect of Sp1 siRNA transfection upon invasiveness of U87 tumor cells under normoxic and hypoxic conditions. 
A. U87 cell invasion at 4 × objectives: N: normoxic incubation, H: hypoxic incubation, U87: control cells, Sp1-DR: U87 cells 
expressing Sp1 siRNA. 1. U87 control cells with transfected empty vector under normoxic conditions. 2. U87 control cells 
subjected to hypoxic incubation. 3. Sp1-deficient U87 cells under normoxic conditions. 4. Sp1-deficient U87 cells under 
hypoxic conditions. B. Invasive cell number compared to normoxic control. *P < 0.05 compared to normoxic control. #P < 
0.05 compared to hypoxic control.Journal of Experimental & Clinical Cancer Research 2009, 28:129 http://www.jeccr.com/content/28/1/129
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anti-invasion effect similar to inhibition of ADAM17.
Here, we used an alpha-secretase assay to determine if Sp1
siRNA influences ADAM17 protease activity. As expected,
hypoxia increased alpha-secretase activity in U87 tumor
cells. However, when Sp1 was down-regulated, hypoxia
did not significantly increase alpha-secretase activity in
line with inhibition of hypoxia-induce ADAM17. Of note,
Sp1 down-regulation did not decrease alpha-secretase
activity under normoxic conditions. This is in agreement
with our previous data that ADAM17 does not constitute
for the majority of alpha-secretase activity in U87 cells
under normoxic conditions, but does account for the
majority of hypoxic-induced alpha-secretase activity [6].
ADAM17 mediates hypoxic-induced glioma invasion
[5,6,26]. To test if Sp1 contributes to the invasion of
tumor cells, we used an in vitro invasion assay. Our results
indicate that under hypoxic conditions the invasive ability
of U87 significantly increased, and this increase was cor-
related with high ADAM17 expression and proteolytic
activity. The invasive ability of U87 cells decreased consid-
erably when Sp1 was suppressed under both normoxic
and hypoxic conditions. Similar to invasion, Sp1 down-
regulation resulted in a significant reduction in U87 cell
migration both under hypoxic and normoxic conditions.
Effect of Sp1 suppression upon migration of U87 tumor cells under normoxic and hypoxic conditions Figure 5
Effect of Sp1 suppression upon migration of U87 tumor cells under normoxic and hypoxic conditions. A. U87 
cell migration at 4× objective. N: normoxic incubation, H: hypoxic incubation, 0 hr: zero hour incubation period, 12 hr: twelve 
hours incubation period, U87: control cells, Sp1-DR: U87 cells expressing Sp1 siRNA. 1. U87 control cells under normoxic 
conditions. 2. U87 control cells under hypoxic incubation. 3. U87 cells expressing Sp1 siRNA under normoxic conditions. 4. 
U87 cells expressing Sp1 siRNA under hypoxic conditions. B. Data are shown as percentage of the initial area covered by 
migration. *P < 0.05 compared to normoxic control. #P < 0.05 compared to hypoxic control.Journal of Experimental & Clinical Cancer Research 2009, 28:129 http://www.jeccr.com/content/28/1/129
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Here we demonstrate that Sp1 is critical for hypoxic-
induced ADAM17, and that Sp1 contributes to hypoxic
induced glioma invasion. However, we have not estab-
lished the effect of Sp1 upon invasion is solely mediated
via ADAM17. In addition to many other genes, HIF-1α
contains Sp1 binding sites in its promoter [17]. In fact, we
found Sp1 down-regulation diminished HIF-1α expres-
sion. Furthermore, the inhibitory effects of Sp1 down-reg-
ulation upon cell invasion and migration were more
pronounced under hypoxic conditions, suggesting the
role of Sp1 is more pronounced in the context of hypoxic-
inducible factors. Hypoxic-induced ADAM17 expression
is dependent upon Sp1, and ADAM17 significantly con-
tributes to hypoxic-induced glioma invasion [6]. How-
ever, it is probable the effect of Sp1 upon hypoxic-induced
cell invasion includes factors in addition to ADAM17.
Our study suggests that Sp1 transcription factor mediates
hypoxia-induced ADAM17 expression and proteolytic
activity, and contributes to an increase in invasiveness of
brain tumor cells under normoxic and hypoxic condi-
tions. These findings suggest that Sp1 may be a novel tar-
get for anti-invasive therapies of brain tumor.
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